Repositorio Dspace

Listar por autor "García-Noblejas, Ana"

Listar por autor "García-Noblejas, Ana"

Ordenar por:Orden:Resultados:

  • Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry 
    Bernal, Teresa; Fernández-Moreno, Ainhoa; de-LaIglesia, Almudena; Benavente, Celina; García-Noblejas, Ana; García-Belmonte, Daniel; Riaza, Rosalía; Salamero, Olga; Foncillas, María-Ángeles; Roldán, Alicia; Noriega-Concepcion, Víctor; Llorente-González, Laura; Bergua-Burgues, Juan-Miguel; Lorente-de-Una, Soraya; Rodríguez-Macías, Gabriela; de-la-Fuente-Burguera, Adolfo; García-Pérez, María-José; López-Lorenzo, José-Luis; Martínez, Pilar; Alaez, Concepción; Callejas, Marta; Martínez-Chamorro, Carmen; Rifon-Roca, José; Amador-Barciela, Lourdes; Mena-Durán, Armando-V; Gómez-Correcha, Karoll; Lavilla-Rubira, Esperanza; Amigo, María-Luz; Vall-llovera, Ferrán; Garrido, Ana; García-Fortes, María; de-Miguel-Llorente, Dunia; Aules-Leonardo, Anastasia; Cervero, Carlos; Coll-Jordá, Rosa; Pérez-Encinas, Manuel-Mateo; Polo-Zarzuela, Marta; Figuera, Ángela; Rad, Guillermo; Martínez-Cuadrón, David; Montesinos, Pau (Wiley, 2023-07)
    BACKGROUND: CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not ...
  • Real-world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B-cell lymphoma: A study from the GELTAMO network 
    Bastos-Oreiro, Mariana; Iacoboni, Gloria; Navarro, Víctor; Martínez, Carolina; Manresa, Pablo; Magnano, Laura; Jiménez-Ubieto, Ana; Vázquez, Sofía; Rodríguez, María-José; Busnego, María-Teresa; del-Campo, Raquel; Paul, Pedro-José; Murillo, Ilda; Donato, Eva-María; Serna, Ángel; Luzardo, Hugo; Gómez, Pilar; Pérez-Ceballos, Elena; Mendibil, Begoña; Ramos, Sergio; García-Noblejas, Ana; González-de-Villambrosia, Sonia; Díaz, Francisco-Javier; López, Javier; Martin-Moro, Fernando; Fernández-Caldas, Paula; Fernández, Rubén; Gutiérrez, Antonio; Sánchez, Blanca; Domínguez, Nazaret; Civeira, María; Villafuerte, Paola; Olazabal, Íñigo; Zeberio, Izaskun; Barrenetxea, Cristina; Gutiérrez, Norma; Romero, Samuel; Martin-Consuegra, Sofía; Huerga, Sofia; Golbano, Nuria; Riaza, Rosaia; Hueso, José-Antonio; Martínez-Barranco, Pilar; Navarro, Belén; Villalon, Lucía; Ortega, Paula; Torres, Ana; Ormenazabal, Íñigo; Sánchez-Anton, María-Piva; Goñi, María-Ángeles; Abrisqueta, Pau; Martin-García-Sancho, Alejandro (WILEY, 2026-06)
  • Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO 
    Gutiérrez, Antonio; Zeberio, Izaskun; Peñalver, Francisco-Javier; Martínez-Barranco, Pilar; Pérez, Sandra; Morillo, Daniel; Martin, Xabier; Nicolás, Concepción; Ferrero, Ainara; Jiménez-Ubieto, Ana; Bastos-Oreiro, Mariana; Dávila-Valls, Julio; Calle, María-Victoria; Pérez, María; Rodríguez, Guillermo; Alonso, Aranzazu; García-Noblejas, Ana; Sánchez-Argüello, Diana; Knight, Teresa; Fernández, Ángeles; López, Javier; Pérez-de-Oteyza, Jaime; González-de-Villambrosia, Sonia; Pérez, Elena; Marín, Alejandro; Navarro, María-Belén; Fernández, Rubén; Gómez, Pilar; Hueso, José-Antonio; Peñarrubia-Ponce, María-Jesús; Bravo, Pilar; García-Belmonte, Daniel; de-la-Nuez, Haridian; Nistal, Sara; Abrisqueta, Pau; Iban, Fernanda; Palomera, Luis; Donato, Eva; Provencio, Andrea; Infante, María-Stefania; González-Barca, Eva (ELSEVIER, 2025-10-14)
    Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) ...